Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Exosens: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Exosens
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Exosens
  • With an expected P/E ratio at 38.59 and 26.53 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Rating Financials

Exosens SectorGermany

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Exosens SectorGermany

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Exosens SectorGermany

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Exosens SectorGermany

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Exosens SectorGermany

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.46B
A
324B
A
250B
A
171B
BBB
161B
A
157B
BB
147B
BB
-
118B
A
90.2B
A
89.64B
A
Average 151.19B
A
Weighted average by Cap.
A